Last $0.04 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/11/14 All times are local (Market data is delayed by at least 15 minutes).

lightlake therapeutics inc (LLTP) Snapshot

Open
$0.04
Previous Close
$0.04
Day High
$0.04
Day Low
$0.04
52 Week High
08/26/13 - $0.11
52 Week Low
06/27/13 - $0.02
Market Cap
6.3M
Average Volume 10 Days
39.7K
EPS TTM
$-0.06
Shares Outstanding
177.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGHTLAKE THERAPEUTICS INC (LLTP)

Related News

No related news articles were found.

lightlake therapeutics inc (LLTP) Related Businessweek News

No Related Businessweek News Found

lightlake therapeutics inc (LLTP) Details

Lightlake Therapeutics Inc., an early stage biopharmaceutical company, develops treatments for common addictions and related disorders. The company focuses on developing a treatment for overweight and obese patients with Binge Eating Disorder. It also develops a treatment for managing the complications of opioid drug addiction; and a treatment for patients with Bulimia Nervosa. Lightlake Therapeutics Inc. has collaboration with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse of the NIDA, part of the NIH, to co-develop a treatment for opioid addiction. The company was formerly known as Madrona Ventures, Inc. and changed its name to Lightlake Therapeutics Inc. in September 2009. Lightlake Therapeutics Inc. was founded in 2005 and is based in London, the United Kingdom.

3 Employees
Last Reported Date: 10/29/13
Founded in 2005

lightlake therapeutics inc (LLTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $206.3K
Executive Chairman
Total Annual Compensation: $193.8K
Chief Financial Officer, Principal Financial ...
Total Annual Compensation: $150.3K
Compensation as of Fiscal Year 2013.

lightlake therapeutics inc (LLTP) Key Developments

Lightlake Therapeutics Inc. Releases Initial Findings of its Clinical Trial with the National Institute on Drug Abuse

Lightlake Therapeutics Inc. announced that the initial findings of its clinical trial with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, supports the company's intranasal delivery of naloxone as a promising innovative treatment for opioid overdose. Initial data from the study shows that the company's naloxone nasal spray potentially can be delivered into the blood stream at least as quickly as the injection process currently used by hospitals, first responders, and others treating opioid overdoses. Naloxone is a medicine currently available through injection that can rapidly reverse the overdose of prescription and illicit opioids. The company, in partnership with NIDA, commenced a two-week clinical trial on September 23, 2013 designed to evaluate the company's intranasal naloxone application.

Lightlake Therapeutics Inc, Annual General Meeting, Dec 17, 2013

Lightlake Therapeutics Inc, Annual General Meeting, Dec 17, 2013., at 19:00 GMT Standard Time. Location: 86 Gloucester Place. Agenda: To authorize to file an amendment to the company's Articles of Incorporation to increase the number of the authorized shares of common stock, par value $0.001 per share, from 200,000,000 to 500,000,000 and reverse stock splits of the outstanding shares of the company's common stock, at a reverse stock split ratio of up to 1 for 50; to elect the board to hold office until 2014 annual meeting of stockholders or until their respective successors have been duly elected and qualified; to hold an advisory vote to approve the compensation of the named executive officers; to hold an advisory vote to determine the frequency of future advisory votes on the compensation of the named executive officers; to ratify the appointment of MaloneBailey, LLP as the company’s independent registered public accounting firm; to consider and act upon any other business as may properly come before the annual meeting or any adjournments thereof.

Lightlake Therapeutics Proposes Amendments to the Company's Articles of Incorporation

Lightlake Therapeutics Inc. at the annual general meeting to be held on December 17, 2013, proposed amendment to the company's articles of incorporation to increase the number of the authorized shares of common stock, par value $0.001 per share, from 200,000,000 to 500,000,000 and to effect reverse stock splits of the outstanding shares of the company's common stock, at a reverse stock split ratio of up to 1 for 50.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLTP:US $0.04 USD 0.00

LLTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LLTP.
View Industry Companies
 

Industry Analysis

LLTP

Industry Average

Valuation LLTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGHTLAKE THERAPEUTICS INC, please visit www.lightlaketherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.